Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 222
Recruiting: 123
Ph III recruiting: 12
Growth YoY: +25%
Industry share: 45%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (94)

clinicaltrialsPublishedShowing 1–11 of 11 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07667400	Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer	not yet recruiting	Phase 1 / Phase 2	120	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT06836726	Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer(EVO)	not yet recruiting	Phase 2	35	University Health Network, TorontoOTHER